GRK1 and cancer: As G-Rg5 and G-Rk1 failed to interact with Annexin A2-K302A, G-Rg5 or G-Rk1 could not inactivate the other pathway triggered NF-κB activation (Figs. 5, 6A and 6B), presenting little anti-cancer activity in Annexin A2-K302A over-expressed HepG2 cells (Fig. 6).